Alzheimer’s and Parkinson’s are the two most rampant neurodegenerative disorders worldwide. Existing
treatments have a limited effect on the pathophysiology but are unable to fully arrest the progression of
the disease. This is due to the inability of these therapeutic molecules to efficiently cross the blood-brain barrier.
We discuss how nanotechnology has enabled researchers to develop novel and efficient nano-therapeutics
against these diseases. The development of nanotized drug delivery systems has permitted an efficient, site-targeted,
and controlled release of drugs in the brain, thereby presenting a revolutionary therapeutic approach.
Nanoparticles are also being thoroughly studied and exploited for their role in the efficient and precise diagnosis
of neurodegenerative conditions. We summarize the role of different nano-carriers and RNAi-conjugated
nanoparticle-based therapeutics for their efficacy in pre-clinical studies. We also discuss the challenges underlying
the use of nanomedicine with a focus on their route of administration, concentration, metabolism, and any
toxic effects for successful therapeutics in these diseases.
Keywords: Nanomedicine, alzheimer's disease, parkinson's disease, nanoparticles, neurodegenerative disease, apoptosis, neuroinflammation,
Rights & PermissionsPrintExport